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This year, the Albert Lasker Basic Medical Research Award will be shared by Douglas Coleman and Jeffrey
Friedman for their discovery of leptin, a hormone that regulates appetite and body weight. By uncovering
a critical physiologic system, their discovery markedly accelerated our capacity to apply molecular and
genetic techniques to understand obesity.Together, Douglas Coleman (left) and Jeffrey Friedman (right) discovered the hormone
leptin, which signals to the brain the state of energy stores in peripheral tissues.The discovery of leptin was a landmark
event in modern physiology. Leptin is a
hormone derived from fat that informs
the brain about the status of energy stores
in peripheral tissues, and its discovery
closed a physiologic feedback loop that
was long hypothesized to control normal
energy homeostasis. Now, the Albert
Lasker Basic Medical Research Award
is recognizing the researchers who pro-
duced this breakthrough, Douglas Cole-
man at The Jackson Laboratory and
Jeffrey Friedman at The Rockefeller Uni-
versity and the Howard Hughes Medical
Institute.
Although the contributions of the two
awardees differed in approach and
occurred three decades apart, their joint
recognition reflects the essential contri-
butions that each researcher made to
this field-changing discovery. Doug Cole-
man is recognized for demonstrating
that a ‘‘satiety factor’’ circulating in the
blood stream was absent in a mutant
mouse strain (ob/ob) that is severely
obese and for correctly predicting that
the hypothalamus is the target of this
factor. Stimulated by Coleman’s results,
Jeffrey Friedman took up the ambitious
goal of cloning the genes mutated in the
mouse strain at a time when such a feat
was extremely difficult. He found that the
ob gene encodes a protein hormone that
reverses obesity and metabolic abnor-
malities in the ob/ob mice. These discov-
eries revised our understanding of inte-
grative metabolism and set the stage for
explosive and still accelerating research
efforts in numerous fields.
Background History
Sometimes in science, a single break-
through changes a field in such a dramatic
way that newcomers to the field have diffi-culty appreciating the ‘‘landscape’’ of the
research prior to the discovery. This is
surely the case for the field of energy
balance regulation before and after the
discovery of leptin. Even 30 years before
leptin’s discovery, a substantial body of
evidence suggested that energy intake
and expenditure were tightly regulated.
For example, when animals were forcibly
overfed (or starved) and then returned to
their original diets, they reliably and often
quite precisely returned to their initial
weights. Clearly, a physiologic homeo-
static system of some type was in play.
Furthermore, it was known that small
lesions in the hypothalamus caused either
obesity or leanness in humans and mice
by disrupting food intake and possiblyReprinted from Cell 14energy expenditure. For some scientists,
these results suggested that regions
within the hypothalamus might be master
regulators of energy balance, integrating
signals from peripheral organs that reflect
the energy status of the organism and
then engaging pathways to adjust nutrient
intake and energy expenditure tomaintain
homeostasis.
Experimental support for this concept
emerged slowly. In 1959, the British phys-
iologist William Hervey published a pre-
scient study reporting the results of surgi-
cally joining normal rats with those given
lesions in the ventromedial hypothalamus
(VMH), which were known to cause
obesity (Hervey, 1959). In these ‘‘parabi-
otic’’ experiments, Hervey connected the3, October 1, 2010 ª2010 Elsevier Inc. 317
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permitting a low-rate exchange of extra-
cellular and blood-borne elements from
one animal to the other. Although Hervey
was not the first researcher to employ
this experimental model, the surgical
unions between these particular rats
generated a particularly interesting result.
As expected, the rats with VMH lesions
becameobese. Surprisingly, however, the
normal rats ingested far less food than
usual and lost substantial weight when
they were joined to the obese rats. Based
on these results, Hervey postulated that
the VMH normally responds to a satiety
signal that regulates feeding. Without a
functional VMH, the rats could not re-
spond to this signal; they became obese
and then overproduced the satiety signal,
which Hervey postulated was a peripheral
factor. Furthermore, Hervey surmised that
high levels of this signal crossed over into
the circulation of the normal rats, sup-
pressing their food intake and weight.
Remarkably, this hypothesis proved to
be correct. However, given the com-
plexity of the parabiotic model used in
the study, more pedestrian explanations
might easily have accounted for the de-
creased food intake of the normal rats.
Plus, identifying a hypothesized hormone
from an unknown site was a daunting
task, which led many in the field to look
elsewhere for interesting experiments to
pursue. Despite much speculation and
the suggestive evidence from this study
and related approaches, no convincing
proof had emerged for the existence of a
specific physiologic system that controls
energy intake, energy expenditure, and
body weight when Douglas Coleman
began to tackle the problem over the
next decade.
Coleman Connects the Dots
Douglas Coleman obtained a doctorate in
biochemistry at the University of Wiscon-
sin and took his first position at The Jack-
son Laboratory in Bar Harbor, Maine in
1958, where he expected to remain for
only a couple of years to extend his under-
standing of genetics. Instead, he spent his
entire career at The Jackson Laboratory
until he retired in 1991. At the beginning,
his research focused on muscle disorders
in mice. However, his most notable ac-
complishments occurred while studying
mice with genetic syndromes of obesity
and diabetes, and at the time, The Jack-318 Reprinted from Cell 143, October 1, 2010son Laboratory was fertile soil for sowing
such studies.
In 1949, an autosomal recessive syn-
drome of severe obesity appeared spon-
taneously in a colony of mice at The
Jackson Laboratory. The mutation map-
ped to chromosome 6 and was desig-
nated obese (ob). In 1966, Coleman and
his associates identified a second obesity
syndrome with very similar symptoms,
but this mutation, designated diabetes
(db), mapped to chromosome 4 (Hummel
et al., 1966). Mice homozygous for both of
these mutations demonstrated dramatic
early onset obesity, insulin resistance
(with varying severity of diabetes), infer-
tility, and a variety of other symptoms,
including hyperphagia (i.e., overeating)
and decreased locomotor activity. Of
interest, when the mutations were bred
onto strains with different genetic back-
grounds, the mice displayed substantial
phenotypic variation in several features,
including the presence of overt diabetes.
The Coleman lab carried out extensive
mouse breeding and phenotyping experi-
ments in an effort to understand how the
genetic background regulates these
metabolic phenotypes, an important but
still largely unresolved question.
Coleman’s most important observa-
tions, however, came from a series of
parabiosis experiments with the mutant
animals. When the subcutaneous tissues
of ob/ob mice were surgically connected
to that of either wild-type or db/db ani-
mals, the ob/ob mice decreased feeding
and lost weight, and this effect reversed
when the union was ended. Control mice
were unaffected by the union with ob/ob
mice (Coleman, 1973). In contrast, when
normal mice were parabiosed to db/db
mice, control mice stopped eating and
lost substantial amounts of weight, but
the db/db mice were unaffected. These
results led Coleman to conclude correctly
that ob/ob mice lacked a satiety factor in
their blood stream that regulates feeding
and weight. Although both the control
and db/db mice supplied this factor to
the ob/ob mice, the db/db mice did so
more robustly. Coleman, therefore, spec-
ulated that db/db mice overproduced the
circulating factor to which they could not
themselves respond but which could be
parabiotically transferred to other animals
to regulate feeding and weight.
Aware of the experiments by Hervey
(1959), Coleman surmised that the hypo-ª2010 Elsevier Inc.thalamus probably contained the center
that responds to the circulating factor.
As with conclusions from Hervey’s
studies, Coleman’s hypothesis proved to
be right on target. However, in the
absence of an identified circulating factor,
many physiologists and obesity investiga-
tors continued to reserve judgment about
the ultimate validity of the Coleman hy-
pothesis, just as they did with Hervey’s
conclusions. Nevertheless, some daring
investigators pursued this hypothesis
and sought to biochemically purify and
identify a factor from fat or other tissues
that regulates food intake. This approach,
although rational, did not succeed. For
a quarter of a century after Coleman’s
insightful experiments, researchers iden-
tified neither a specific factor, its site of
origin, nor its site of action. In fact, many
leaders of the field questioned whether
the efforts to find such a factor were
scientifically justified.
Friedman Finds the Genes
Enter Jeffrey Friedman, two decades after
Coleman’s work. Trained as a physician,
Friedman initially intended to become a
gastroenterologist. However, the emerg-
ing power of molecular genetics lured
him into a basic science laboratory to
study physiology and disease. Working
at The Rockefeller University, where he
obtained a PhD in the laboratory of James
Darnell Jr., Friedman became interested
in the genetics of body weight regulation
and decided to tackle the daunting task
of cloning the ob gene. Initially in collabo-
ration with other obesity researchers at
Rockefeller, including Rudolph Leibel,
Friedman methodically attacked this
goal and ultimately accomplished it. The
results led to insights that were nothing
short of breathtaking.
In a classic 1994 Nature paper, Fried-
man and colleagues described the ob
gene as a 4.5 kb transcript expressed
exclusively inadipose tissueandpredicted
to encode a secreted peptide with 167
amino acids (Zhang et al., 1994). More-
over, the transcript was disrupted in both
available ob alleles. Soon after this initial
paper, the Friedman group and two others
laboratories demonstrated that treating
ob/ob mice with the recombinant peptide
dramatically corrected the animal’s
obesity and hyperphagia (Halaas et al.,
1995). Thus, the peptide was named ‘‘lep-
tin’’ from the Greek root leptos for ‘‘thin.’’
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when injected directly into the CNS than
into the blood stream, suggesting that
the primary target of leptin is in the CNS,
as Coleman predicted. Furthermore, lep-
tin failed to act in db/dbmice, which nicely
ruled out a nonspecific basis for the
weight loss and confirmed Coleman’s
hypothesis about the db/db mice lacking
the ability to detect the circulating satiety
factor. Thus, after almost a half a century
of searching, the biochemical cause of
obesity of the ob/ob mouse was finally
understood.
In work that soon followed, the Fried-
man laboratory and one other group found
that thedb locus encodes a family of leptin
receptors that are alternatively spliced
and members of the cytokine receptor
family (Lee et al., 1996). The db allele
altered only a single splice variant that,
unlike the other variants, is expressed
strongly in the hypothalamus. This variant
wasalso theonly leptin receptor predicted
to mediate signaling through the Jak/Stat
pathway. Not surprisingly, the Friedman
laboratory soon demonstrated that leptin
activates STAT3 in the hypothalamus
when it is systemically administered
(Vaisse et al., 1996). Furthermore, selec-
tively deleting this leptin receptor variant
from neurons recapitulates the major
features of the ob/ob syndrome.
Together, these findings demonstrated
the existence of a previously unknown
endocrine system through which the
status of energy stores in fat is communi-
cated by the hormone leptin to regulatory
centers in the brain. Absence of either the
ligand or the receptor caused severe and
similar obesity syndromes, revealing the
critical importance of this pathway and
its potential relevance to human disease.
Needless to say, this discovery trans-
formed the field of nutritional metabolism.
Leptin Research Today
Over the ensuing 15 years, researchers
have learned much more about the
biology and pathophysiology of leptin.
Indeed, a PubMed search for ‘‘leptin’’
reveals more than 18,000 citations. The
major developments in this intensive
area of research can be grouped into
three areas: the physiologic role of leptin;
how leptin’s action is limited in human
obesity induced by diet or the environ-
ment; and the neural and peripheral
circuits upon which leptin acts.Initially, leptin was thought of as amole-
cule produced by excess adipose tissue
to provide a negative feedback signal to
the brain to limit obesity by reducing
appetite and increasing energy expendi-
ture. However, new data and physiologic
thinking have substantially extended
this initial understanding. Clearly, leptin
reverses the syndrome of ob/ob mice,
and recombinant leptin has equally
dramatic effects on obese humans with
rare loss-of-function mutations in the lep-
tin gene (Farooqi et al., 1999). However,
disappointingly, both mice and humans
with more common forms of obesity typi-
cally have high levels of leptin, and more
importantly, their body weights respond
weakly or not at all to pharmacologic
supplementation of leptin (Heymsfield
et al., 1999). This suggests that ‘‘common
obesity’’ is a state of leptin resistance, as
opposed to leptin deficiency.
Of interest, obesity has long been
known to be a state of resistance to in-
sulin, the preeminent metabolic hormone.
Numerous studies have characterized the
molecular mechanisms and implications
of insulin resistance associated with
obesity. In obese patients, raising already
high levels of insulin even further with
exogenous doses typically lowers blood
glucose, revealing that the resistance to
insulin action on blood glucose is relative,
not absolute. In contrast, raising leptin
levels even further in the obese state has
minimal effects on body weight, suggest-
ing that leptin resistance to this important
endpoint is almost absolute. Conse-
quently, the identification of the molecular
mechanisms underlying leptin resistance
is a central question to address if we are
to understand the pathophysiology of
obesity as it occurs in most people.
Studies in mice have identified two
likely mediators of leptin resistance. The
most well-characterized one, suppressor
of cytokine signaling 3 (SOCS3) (Bjørbaek
et al., 1998), is an intracellular inhibitor of
Jak/Stat signaling. Leptin acutely induces
expression of SOCS3 in target neurons,
and SOCS3 expression is also increased
in the hypothalamus of mice with diet-
induced obesity. Most decisively, disrupt-
ing the function of SOCS3 enhances
leptin signaling and limits obesity when
susceptible mice are placed on diets
that cause obesity (Howard et al., 2004).
A second candidate for an inhibitor of
leptin signaling is the tyrosine phospha-Reprinted from Cell 14tase PTP1b. As with SOCS3, disrupting
PTP1b protects against diet-induced
obesity (Zabolotny et al., 2002).
The most critical leptin signals are ex-
erted in the hypothalamus. The hypothal-
amus cannot be probed experimentally in
humans, and thus, our capacity to assess
the roles of SOCS3 and PTP1b in human
obesity is currently limited. Until ap-
proaches are identified to counter these
inhibitory pathways, the existence of lep-
tin resistance in humans will limit the ther-
apeutic potential of leptin. Nevertheless,
researchers are still actively searching
for obese individuals that respond to lep-
tin alone or in combination with other
therapies.
It seems likely that leptin will also have
therapeutic potential in disorders distinct
from obesity. Several states of ‘‘low lep-
tin’’ are associated neither with obesity
nor with mutations of the leptin gene.
For example, leanness and low body fat
can cause low levels of leptin in women
athletes, leading to amenorrhea and
anovulation, and leptin supplementation
may restore reproductive capacity in
these cases (Welt et al., 2004). In patients
with syndromes of ‘‘lipodystrophy,’’ mul-
tiple causes lead to a deficiency of
adipose tissue and thus leptin. Treatment
with leptin dramatically improves fatty
liver and insulin resistance in these
patients (Petersen et al., 2002).
Although a threshold of leptin action is
clearly required for preventing severe
obesity, this ‘‘anti-obesity’’ function para-
doxically may not be the singular or even
dominant physiologic role of leptin. Leptin
levels rise in obesity, consistent with lep-
tin’s function as a negative feedback
signal of energy stores. However, leptin
expression and circulating levels fall
quickly when normal mice and humans
are starved. May leptin be a signal for
adapting to starvation, as well as a signal
for resisting excessive weight gain?
In addition to increased hunger, starva-
tion induces a specific array of adaptive
endocrine and metabolic consequences,
including, most prominently, the suppres-
sion of reproductive capacity and de-
creased thyroid function. Importantly,
these changes are severely blunted when
leptin levels are kept constant by exoge-
nous supplementation during starvation
of mice (Ahima et al., 1996). This finding
led to the hypothesis that falling leptin is
the dominant signal for initiating a broad3, October 1, 2010 ª2010 Elsevier Inc. 319
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Indeed, the predicted impairments of
endocrine function during starvation are
also seen in ob/ob mice, such that these
mutant mice are actually experiencing
the physiology of starvation despite their
severe obesity. We now understand that
these two faces of leptin, mediating both
the response to starvation as levels fall
and the response to overfeeding as levels
rise, represent the full range of leptin
biology. In 1998, we hypothesized that
leptin resistance of weight regulatory
pathwaysduring periods of energy excess
provides an evolutionary advantage; it
limits the capacity of leptin to keep an indi-
vidual excessively lean, which would
cause amore rapid demise during periods
of food deprivation.
Thediscoveryof leptinhasalsoprovided
apowerful tool toexplore thecentral neural
circuits that control energy balance and
related physiologies. A new era in the
neurobiology of energy balance has been
ushered in by the localization of leptin
receptors in specific regions of the hypo-
thalamus and the characterization of the
leptin’s ability to modulate expression of
neuropeptides involved in regulation of
appetite and body weight. Researchers
have demonstrated that leptin reduces
expression of several neuropeptides that
potently stimulate feeding, such as Neuro-
peptide Y (NPY), Agouti-related protein
(AgRP), and melanin concentrating
hormone (MCH).Conversely, leptin admin-
istration stimulates expression of neuro-
peptides that suppress feeding and
weight. For example, when neurons ex-
pressing pro-opiomelanocortin (POMC)
are stimulated by leptin, they produce the
neuropeptide aMSH, which stimulates
centralmelanocortin 4 receptors ondown-
stream neurons. The consequence of this
stimulation is to suppress food intake and
body weight. The critical relevance of this
melanocortin circuit is evident not only
from its identity as a target of leptin activa-
tion, but also from the fact that loss of func-320 Reprinted from Cell 143, October 1, 2010tion of the cognate melanocortin 4
receptor is the most common genetic
cause of human obesity, accounting for
3%–5%of severe obesity in humans. Lep-
tin also has direct and indirect actions in
brain regions apart from hypothalamus,
and it is clear that the full integrated
circuitry of leptin action in brain will require
much additional research.
Conclusions
What lessons can we learn from the
discovery of leptin? First, indirect argu-
ments or data supporting the existence
of a physiologic system can be heuristi-
cally important and can serve as strong
stimuli to drive groundbreaking research.
Nevertheless, no matter how compelling,
such arguments are often unconvincing
to the scientific community until the
specific molecules underlying the physi-
ology are identified. Second, the dis-
covery of a powerful regulator of appetite,
energy balance, and body weight can still
leave many outstanding questions about
the mechanisms underlying disorders of
body weight in humans. This can frustrate
efforts to translate the discovery into an
effective therapy for common forms of
obesity. Finally, we should take note of
the fact that both The Rockefeller Univer-
sity and Howard Hughes Medical Institute
believed in Jeff Friedman’s research pro-
ject and supported his efforts during
many years of hard work when tangible
results were few and far between. The
ability to make such long-term bets on
people and their projects is difficult for
funding agencies and institutions. We
should celebrate the cases in which such
confidence and support is given, espe-
cially when the researchers are successful
and prove that the outcome was well
worth the risk, as was the case here.
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